ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines. The company’s lead candidate IMX 101 is a vaccine against Helicobacter pylori, which colonizes the stomach and is the cause of ulcer disease and gastric cancer in humans. Founder Markus Gerhard and his team discovered that the colonization ability (and hence, the infectiousness) of H. pylori depends on a secreted bacterial factor that down-regulates the host immune system. Many other highly infectious pathogens have evolved similar immune evasion mechanisms, which are the focus of the ImevaX screening program.

Patents 18show all

  • 18
    A61K - Preparations for medical, dental, or toilet purposes
  • 18
    C07K - Peptides
  • 18
    C12N - Microorganisms or enzymes
  • 18
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 18
    C12Y - Enzymes
  • 18
    G01N - Investigating or analysing materials by determining their chemical or physical properties

Clinical Trials 1show all

1Phase 1

Contact Information

Grillparzerstr. 18, Munich
Munich 81675
Germany

Overview

Total FundingEmployeesLast Funding DateStatus
$17,297,852unknown2015-03-02Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-09-01$7,746,268GrantGerman Federal Ministry of Education and Research (BMBF)
2015-03-02Series A
2014-10-28$9,551,584Series AWellington PartnersEMBL Ventures, BioMedPartners, Santo Venture Capital